Commercial production of P9 unit is expected to commercialize by end of Q2 FY23 whereas we are targeting P10 unit to commence by end of this financial year
Performance Surfactants volume stood at 35,443 MT for Q1 FY23, down by 8.6% on a YoY basis whereas Specialty Care Products volume stood at 19,829 MT for Q1 FY23, down by 6% on a YoY basis
Consolidated PAT from continuing operations for the quarter ended June 2022 stood at Rs. 641 crore
The sustained focus on speciality films in the last 2-3 years and ongoing improvement of internal efficiencies helped the company achieve higher EBITDA despite margin pressure
The agrochemicals industry is confident that they would be able to increase export of inputs like pesticides and fertilizers, besides increasing export of food
The company reported total income of Rs. 92.09 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 131.82 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 711.56 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 121.89 crores during the period ended June 30, 2022.
The company expects challenges to persist in terms of global supply of Roundup (glyphosate) in the near term.
The company has reported total income of Rs. 525.01 crores during the period ended June 30, 2022.
BPCL has reported Revenue from Operations of Rs 1,38,405.79 crores for the quarter April-June 2022 Vs Rs.89,688.98 Crs in the corresponding comparative quarter.
The urea melt plant with a pool reactor will use Stamicarbon’s MP Flash Design which is part of the LAUNCH MELT series and the Fluid bed Granulation design including acidic scrubbing which is part of the LAUNCH FINISH series
The Committee will examine different options and also engage the services of experts such as lawyers, financial advisors, valuer, merchant banker, etc. as may be required and submit its recommendations to the board for consideration
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
The strong topline performance was driven by incremental benefits accruing from the expanded capacity and was supported by continued positive demand across key products
The company is planning a Capex outflow of Rs. 70 crore for FY23 which will target further increase Sandila plant capacity by 4,000 MT
Baroda plant to be commissioned by June 2023, Mahad plant by H1 2023, and Bareilly plant by October 2022
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Subscribe to our newsletter & stay updated.
